NSCLC patients will most commonly be tested for mutations in epidermal growth factor receptors (EGFR), anaplastic lymphoma kinase (ALK) and Kirsten rat sarcoma viral oncogene homolog (KRAS). This evidence concerns the gene ALK and non-small cell lung carcinoma.